RU2001107028A - COMPOUNDS AS SELECTIVE AGONISTS OF ALPHA-ADRENERGIC RECEPTORS 2B OR 2B / 2C - Google Patents
COMPOUNDS AS SELECTIVE AGONISTS OF ALPHA-ADRENERGIC RECEPTORS 2B OR 2B / 2CInfo
- Publication number
- RU2001107028A RU2001107028A RU2001107028/04A RU2001107028A RU2001107028A RU 2001107028 A RU2001107028 A RU 2001107028A RU 2001107028/04 A RU2001107028/04 A RU 2001107028/04A RU 2001107028 A RU2001107028 A RU 2001107028A RU 2001107028 A RU2001107028 A RU 2001107028A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- subtype
- receptors
- adrenergic
- oxo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 108
- 239000000556 agonist Substances 0.000 title claims 7
- 102000004305 alpha adrenergic receptors Human genes 0.000 title 1
- 108090000861 alpha adrenergic receptors Proteins 0.000 title 1
- 102000005962 receptors Human genes 0.000 claims 26
- 108020003175 receptors Proteins 0.000 claims 26
- 102000017910 Adrenergic receptor family Human genes 0.000 claims 22
- 108060003345 Adrenergic receptor family Proteins 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 19
- 125000004043 oxo group Chemical group O=* 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 230000001800 adrenalinergic Effects 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 238000004458 analytical method Methods 0.000 claims 6
- 125000004432 carbon atoms Chemical group C* 0.000 claims 6
- 230000000271 cardiovascular Effects 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 230000001624 sedative Effects 0.000 claims 6
- 239000000932 sedative agent Substances 0.000 claims 6
- 231100000486 side effect Toxicity 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 101710039842 ADORA2A Proteins 0.000 claims 3
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 3
- 206010002855 Anxiety Diseases 0.000 claims 3
- 206010057666 Anxiety disease Diseases 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 206010012735 Diarrhoea Diseases 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 206010061255 Ischaemia Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 208000008238 Muscle Spasticity Diseases 0.000 claims 3
- 208000003067 Myocardial Ischemia Diseases 0.000 claims 3
- 206010028748 Nasal obstruction Diseases 0.000 claims 3
- 208000004296 Neuralgia Diseases 0.000 claims 3
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 3
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 206010061920 Psychotic disease Diseases 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 229960003679 brimonidine Drugs 0.000 claims 3
- 201000006233 congestive heart failure Diseases 0.000 claims 3
- 201000008286 diarrhea Diseases 0.000 claims 3
- 230000027939 micturition Effects 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000000007 visual effect Effects 0.000 claims 3
- 206010013754 Drug withdrawal syndrome Diseases 0.000 claims 2
- 102100001490 FAM168B Human genes 0.000 claims 2
- 101710039387 FAM168B Proteins 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N Oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims 2
- 208000004880 Polyuria Diseases 0.000 claims 2
- 241000025483 Symphonia globulifera Species 0.000 claims 2
- 239000000048 adrenergic agonist Substances 0.000 claims 2
- 230000001270 agonistic Effects 0.000 claims 2
- 125000004429 atoms Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 230000001149 cognitive Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000035619 diuresis Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 230000004410 intraocular pressure Effects 0.000 claims 2
- 229960001528 oxymetazoline Drugs 0.000 claims 2
- 230000025627 positive regulation of urine volume Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 206010004938 Bipolar disease Diseases 0.000 claims 1
- 206010027175 Memory impairment Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000036151 Urine output Effects 0.000 claims 1
- 206010048010 Withdrawal syndrome Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000003930 cognitive ability Effects 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000002550 fecal Effects 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 230000003389 potentiating Effects 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Claims (1)
где пунктирные линии представляют собой возможные двойные связи;
R представляет собой Н или низший алкил;
Х представляет собой S или C(H)R1, где R1 представляет собой Н или низший алкил, либо R1 отсутствует, когда Х представляет собой S или когда связь между Х и кольцом, представленным формулой
является двойной связью;
Y представляет собой О, N, S, (CRx 1)y, где у является целым числом от 1 до 3, -СН= СН- или -Y1CH2-, где Y1 представляет собой О, N или S; x является целым числом 1 или 2, причем х= 1, когда R2, R3 или R4 связан с ненасыщенным атомом углерода, и х= 2, когда R2, R3 или R4 связан с насыщенным атомом углерода;
R2 представляет собой Н, низший алкил, галоген, гидрокси, низшую алкоксигруппу, низший алкенил, ацил или низший алкинил, либо R2 может представлять собой оксо, когда он присоединен к насыщенному атому углерода;
каждый из R3 и R4 представляет собой Н, низший алкил, галоген, низший алкенил, ацил, низший алкинил, арил, гетероарил или замещенный арил или гетероарил, где указанный заместитель представляет собой галоген, низший алкил, низшую алкоксигруппу, низший алкенил, ацил, низший алкинил, нитро, циано, трифторметил, гидрокси или фенил, либо вместе они представляют собой -(C(R2)x)z-; -Y1(C(R2)x)'z-; -Y1(С(R2)x)yY1-; (C(R2)x)-Y1-(C(R2)x)-;
-(C(R2)x)-Y1-(C(R2)x)-(C(R2)x)- и -Y1-(C(R2)x)-Y1-(C(R2)x)-, где z является целым числом от 3 до 5, z' является целым числом от 2 до 4, а х и у являются такими, как определено выше, и кроме того любой конец каждой из этих двухвалентных группировок может быть присоединен либо к R3, либо к R4 с образованием конденсированной кольцевой структуры
и образованное таким образом кольцо может быть полностью ненасыщенным, частично ненасыщенным или полностью насыщенным при условии, что углерод кольца имеет валентность не более чем 4, азот имеет валентность не более чем 3, а О и S имеют валентность не более чем 2, и в том числе его энантиомеры и фармацевтически приемлемые соли.1. A compound having selective agonistic activity against adrenergic receptors of subtype (s) α2B or α2B / α2C compared to adrenergic receptors of subtype 2A, represented by the formula
where the dashed lines represent possible double bonds;
R represents H or lower alkyl;
X represents S or C (H) R 1 , where R 1 represents H or lower alkyl, or R 1 is absent when X represents S or when the bond between X and the ring represented by the formula
is a double bond;
Y represents O, N, S, (CR x 1 ) y , where y is an integer from 1 to 3, —CH = CH— or —Y 1 CH 2 -, where Y 1 represents O, N or S; x is an integer of 1 or 2, wherein x = 1 when R 2 , R 3 or R 4 is bonded to an unsaturated carbon atom, and x = 2 when R 2 , R 3 or R 4 is bonded to a saturated carbon atom;
R 2 represents H, lower alkyl, halogen, hydroxy, lower alkoxy, lower alkenyl, acyl or lower alkynyl, or R 2 may be oxo when it is attached to a saturated carbon atom;
each of R 3 and R 4 represents H, lower alkyl, halogen, lower alkenyl, acyl, lower alkynyl, aryl, heteroaryl or substituted aryl or heteroaryl, wherein said substituent is halogen, lower alkyl, lower alkoxy, lower alkenyl, acyl , lower alkynyl, nitro, cyano, trifluoromethyl, hydroxy or phenyl, or together they represent - (C (R 2 ) x ) z -; -Y 1 (C (R 2 ) x ) ' z -; -Y 1 (C (R 2 ) x ) y Y 1 -; (C (R 2 ) x ) -Y 1 - (C (R 2 ) x ) -;
- (C (R 2 ) x ) -Y 1 - (C (R 2 ) x ) - (C (R 2 ) x ) - and -Y 1 - (C (R 2 ) x ) -Y 1 - (C (R 2 ) x ) -, where z is an integer from 3 to 5, z 'is an integer from 2 to 4, and x and y are as defined above, and in addition, either end of each of these divalent groups may be attached to either R 3 or R 4 to form a fused ring structure
and the ring thus formed can be completely unsaturated, partially unsaturated or completely saturated, provided that the carbon of the ring has a valency of not more than 4, nitrogen has a valency of not more than 3, and O and S have a valency of not more than 2, and including its enantiomers and pharmaceutically acceptable salts.
3. Соединение по п. 2, где Х представляет собой C(H)R1.2. The compound according to claim 1, which is represented by the formula
3. The compound of claim 2, wherein X is C (H) R 1 .
представляет собой фуранильный радикал.5. The compound according to claim 4, where R 2 represents H, and
is a furanyl radical.
представляет собой тиенильный радикал.7. The compound according to claim 4, where R 2 represents H, and
represents a thienyl radical.
представляет собой циклогексильный радикал.12. The compound of claim 4, wherein
is a cyclohexyl radical.
15. Соединение по п. 12, где R2 представляет собой диметил, а R3 и R4 вместе представляют собой (СН)4.14. The compound according to p. 12, where R 2 represents H, and R 3 and R 4 together represent (CH 2 ) 4
15. The compound of claim 12, wherein R 2 is dimethyl and R 3 and R 4 together are (CH) 4 .
представляет собой циклопентильный радикал.19. The compound of claim 4, wherein
is a cyclopentyl radical.
представляет собой фенильный радикал.21. The compound of claim 4, wherein
represents a phenyl radical.
где Y представляет собой S или О.22. The compound according to claim 1, which has the formula
where Y represents S or O.
24. Соединение по п. 23, где R3 и R4 вместе представляют собой (СН)4.23. The compound according to claim 1, which has the formula
24. The compound of claim 23, wherein R 3 and R 4 together are (CH) 4 .
представляет собой фенил.39. The compound of claim 2, wherein X is S and
represents phenyl.
представляет собой фуранил.40. The compound of claim 3, wherein R 1 is methyl, and
is furanyl.
представляет собой фенильный радикал, а R3 и R4 вместе представляют собой O(CR2)2O.44. The compound of claim 3, wherein R is CH 3 ,
represents a phenyl radical, and R 3 and R 4 together represent O (CR 2 ) 2 O.
представляет собой циклопентильный радикал, a R2 представляет собой оксо.45. The compound of claim 2, wherein X is CH,
represents a cyclopentyl radical, and R 2 represents oxo.
47. Соединение по п. 1, представленное формулой
где Y представляет собой (Rx 1)2, R3 + R4 представляет собой (C(R2)x)4, и Х присоединен по одному из двух положений кольца, указанных волнистой линией, а оставшееся положение занимает водород, при условии, что две двойные связи не могут быть у одного и того же атома кольца.46. The compound represented by formula
47. The compound of claim 1, represented by formula
where Y is (R x 1 ) 2 , R 3 + R 4 is (C (R 2 ) x ) 4 , and X is attached at one of two positions of the ring indicated by the wavy line, and the remaining position is hydrogen, provided that two double bonds cannot be on the same ring atom.
где (R2)x представляет собой водород или оксо.48. The compound of claim 47, which is represented by the formula
where (R 2 ) x represents hydrogen or oxo.
50. Соединение по п. 50, где структура представляет собой
51. Соединение по п. 2, где R представляет собой водород, R3 и R4 представляют собой -(C(R2)x-N-(C(R2)x)-(C(R2)x)-, и Х представляет собой CHR1, как представлено формулой
причем группа CHR1 присоединена по одному из двух положений кольца, указанных волнистой линией, а оставшееся положение занимает водород, и при условии, что две двойные связи не могут быть у одного и того же атома кольца.49. The compound of claim 47, the structure of which is
50. The compound of claim 50, wherein the structure is
51. The compound of claim 2, wherein R is hydrogen, R 3 and R 4 are - (C (R 2 ) x —N— (C (R 2 ) x ) - (C (R 2 ) x ) - , and X represents CHR 1 as represented by the formula
moreover, the CHR 1 group is attached at one of the two positions of the ring indicated by the wavy line, and the remaining position is occupied by hydrogen, and provided that two double bonds cannot be on the same atom of the ring.
и (R2)x представляет собой водород или оксо.52. The compound of claim 51, which has the formula
and (R 2 ) x represents hydrogen or oxo.
и (R2)x представляет собой водород или оксо.53. The compound of claim 51, which has the formula
and (R 2 ) x represents hydrogen or oxo.
и Y1 представляет собой N или О или S, как представлено формулой
где X и X' выбраны из группы, состоящей из N, О и С, и по меньшей мере один из Х и X' представляет собой N.54. The compound of claim 1, wherein R 3 and R 4 are selected from the group consisting of —Y 1 - (C (R 2 ) x ) - (C (R 2 ) x ) —Y 1 -, —Y 1 - (C (R 2 ) x ) - (C (R 2 ) x ) - (C (R 2 ) x ) -,
and Y 1 represents N or O or S as represented by the formula
where X and X 'are selected from the group consisting of N, O and C, and at least one of X and X' is N.
где (R2)x представляет собой водород или оксо.55. The compound of claim 54, which is represented by the formula
where (R 2 ) x represents hydrogen or oxo.
где (R2)x представляет собой водород или оксо.56. The compound of claim 54, which is represented by the formula
where (R 2 ) x represents hydrogen or oxo.
и его фармацевтически приемлемые соли.57. A compound having selective agonistic activity against adrenergic receptors of subtype (s) α2B or α2B / α2C compared to adrenergic receptors of subtype 2A, represented by the formula
and its pharmaceutically acceptable salts.
где пунктирные линии представляют собой возможные двойные связи; R представляет собой Н или низший алкил; Х представляет собой S или C(H)R1, где R1 представляет собой Н или низший алкил, либо R1 отсутствует, когда Х представляет собой S или когда связь между Х и кольцом, представленным формулой
является двойной связью; Y представляет собой О, N, S, (CRx 1)y, где у является целым числом от 1 до 3, -СН= СН- или -Y1CH2-, где Y1 представляет собой О, N или S; x является целым числом 1 или 2, причем х= 1, когда R2, R3 или R4 связан с ненасыщенным атомом углерода, и х= 2, когда R2, R3 или R4 связан с насыщенным атомом углерода; R2 представляет собой Н, низший алкил, галоген, гидрокси или низшую алкоксигруппу, либо R2 может представлять собой оксо, когда он присоединен к насыщенному атому углерода; каждый из R3 и R4 представляет собой Н, низший алкил, гидрокси, низшую алкоксигруппу или фенил, либо вместе они представляют собой -(C(R2)x)z-; -Y1(R2)x)'z; -Y1(С(R2)x)yY1-; -(C(R2)x)-Y1-(C(R2)x)-; -(C(R2)x)-Y1-(C(R2)x)-(C(R2)x)- и
-Y1-(C(R2)x)-Y1-(C(R2)x)-, где z является целым числом от 3 до 5, z' является целым числом от 2 до 4, а х и у являются такими, как определено выше, и кроме того любой конец каждой из этих двухвалентных группировок может быть присоединен либо к R3, либо к R4 с образованием конденсированной кольцевой структуры
и образованное таким образом кольцо может быть полностью ненасыщенным, частично ненасыщенным или полностью насыщенным при условии, что углерод кольца имеет валентность не более чем 4, азот имеет валентность не более чем 3, а О и S имеют валентность не более чем 2; или
где W представляет собой бициклический радикал, выбранный из группы, состоящей из
где R5, R6, R7 и R8 выбраны из группы, состоящей из Н и низшего алкила, при условии, что по меньшей мере один из R5 и R6 или R6 и R7 представляет собой OC(R9)C(R9)N(R) с образованием конденсированного кольца с
где R9 представляет собой Н, низший алкил или оксо,
и
где R10 представляет собой Н, низший алкил, фенил или фенил, замещенный низшим алкилом, a Z представляет собой О или NH.74. The method according to PP. 58, 65 or 71, where the active compound is selected from the group consisting of compounds having the formula
where the dashed lines represent possible double bonds; R represents H or lower alkyl; X represents S or C (H) R 1 , where R 1 represents H or lower alkyl, or R 1 is absent when X represents S or when the bond between X and the ring represented by the formula
is a double bond; Y represents O, N, S, (CR x 1 ) y , where y is an integer from 1 to 3, —CH = CH— or —Y 1 CH 2 -, where Y 1 represents O, N or S; x is an integer of 1 or 2, wherein x = 1 when R 2 , R 3 or R 4 is bonded to an unsaturated carbon atom, and x = 2 when R 2 , R 3 or R 4 is bonded to a saturated carbon atom; R 2 represents H, lower alkyl, halogen, hydroxy or lower alkoxy, or R 2 may be oxo when it is attached to a saturated carbon atom; each of R 3 and R 4 represents H, lower alkyl, hydroxy, lower alkoxy or phenyl, or together they represent - (C (R 2 ) x ) z -; -Y 1 (R 2 ) x ) 'z; -Y 1 (C (R 2 ) x ) y Y 1 -; - (C (R 2 ) x ) -Y 1 - (C (R 2 ) x ) -; - (C (R 2 ) x ) -Y 1 - (C (R 2 ) x ) - (C (R 2 ) x ) - and
-Y 1 - (C (R 2 ) x ) -Y 1 - (C (R 2 ) x ) -, where z is an integer from 3 to 5, z 'is an integer from 2 to 4, and x and y are as defined above, and in addition, either end of each of these divalent moieties can be attached to either R 3 or R 4 to form a fused ring structure
and the ring thus formed can be completely unsaturated, partially unsaturated, or fully saturated, provided that the ring carbon has a valency of not more than 4, nitrogen has a valency of not more than 3, and O and S have a valency of not more than 2; or
where W is a bicyclic radical selected from the group consisting of
where R 5 , R 6 , R 7 and R 8 are selected from the group consisting of H and lower alkyl, provided that at least one of R 5 and R 6 or R 6 and R 7 is OC (R 9 ) C (R 9 ) N (R) to form a fused ring with
where R 9 represents H, lower alkyl or oxo,
and
where R 10 represents H, lower alkyl, phenyl or phenyl substituted with lower alkyl, and Z represents O or NH.
представляет собой циклопентенильный или циклогексенильный радикал.81. The compound of claim 4, wherein
represents a cyclopentenyl or cyclohexenyl radical.
представляет собой циклогексенильный радикал.82. The compound of claim 81, wherein
represents a cyclohexenyl radical.
представляет собой
a R2 представляет собой водород и метил.83. The compound of claim 82, wherein
represents
a R 2 represents hydrogen and methyl.
представляет собой
а R2 представляет собой водород.85. The compound of claim 82, wherein
represents
and R 2 represents hydrogen.
представляет собой циклопентенильный радикал.87. The compound of claim 81, wherein
represents a cyclopentenyl radical.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32975299A | 1999-06-10 | 1999-06-10 | |
US09/329,752 | 1999-06-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2001107028A true RU2001107028A (en) | 2003-02-27 |
RU2232154C2 RU2232154C2 (en) | 2004-07-10 |
Family
ID=23286854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2001107028/04A RU2232154C2 (en) | 1999-06-10 | 2000-06-08 | Substituted derivatives of imidazole, method for administration of pharmaceutical composition and method for treatment based on these compounds |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1104407B1 (en) |
AT (1) | ATE283843T1 (en) |
AU (1) | AU773668B2 (en) |
CZ (1) | CZ2001864A3 (en) |
DE (1) | DE60016359T2 (en) |
ES (1) | ES2228544T3 (en) |
HK (1) | HK1035724A1 (en) |
HU (1) | HUP0104390A3 (en) |
RU (1) | RU2232154C2 (en) |
TW (1) | TWI283669B (en) |
WO (1) | WO2001000586A1 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
AU2002254265B2 (en) * | 1997-12-04 | 2008-05-15 | Allergan, Inc. | Imidiazole derivatives and their use as agonists selective at alpha 2B or 2B/2C adrenergic receptors |
FI20000073A0 (en) * | 2000-01-14 | 2000-01-14 | Orion Yhtymae Oy | New imidazole derivatives |
US6388090B2 (en) | 2000-01-14 | 2002-05-14 | Orion Corporation | Imidazole derivatives |
US6534542B2 (en) | 2001-02-27 | 2003-03-18 | Allergen Sales, Inc. | (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors |
US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
US7358269B2 (en) | 2002-05-21 | 2008-04-15 | Allergan, Inc. | 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one |
US7276522B2 (en) | 2002-05-21 | 2007-10-02 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7323485B2 (en) | 2002-05-21 | 2008-01-29 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7345065B2 (en) | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
US7091232B2 (en) * | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
WO2005039567A1 (en) * | 2003-10-08 | 2005-05-06 | Allergan, Inc. | Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides |
WO2005111038A2 (en) * | 2004-05-07 | 2005-11-24 | Memory Pharmaceuticals Corporation | 1h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof |
JP2008514602A (en) | 2004-09-24 | 2008-05-08 | アラーガン、インコーポレイテッド | 4- (Fused ring methyl) -imidazole-2-thione as α2 adrenergic agonist |
BRPI0516083A (en) | 2004-09-24 | 2008-08-19 | Allergan Sales Inc | 4- (phenylmethyl and substituted 4-phenylmethyl) -imidazol-2-thiones acting as alpha2 adrenergic agonists |
CA2581828A1 (en) | 2004-09-24 | 2006-04-06 | Allergan, Inc. | 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists |
KR101202066B1 (en) | 2004-09-28 | 2012-11-15 | 알러간, 인코포레이티드 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same |
US7390829B2 (en) | 2005-06-29 | 2008-06-24 | Allergan, Inc. | Alpha-2 adrenergic agonists |
US7700592B2 (en) | 2005-08-25 | 2010-04-20 | Schering Corporation | α2C adrenoreceptor agonists |
EP1945626B1 (en) * | 2005-08-25 | 2011-07-27 | Schering Corporation | Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists |
US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
AR057771A1 (en) | 2005-08-25 | 2007-12-19 | Pharmacopeia Drug Discovery | ALFA2C ADRENORECEPTORS AGONISTS |
US7592362B2 (en) | 2006-01-19 | 2009-09-22 | Pfizer Limited | Substituted imidazoles |
US7323477B2 (en) | 2006-02-02 | 2008-01-29 | Allergan, Inc. | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline |
RU2456281C2 (en) * | 2006-11-16 | 2012-07-20 | Ф. Хоффманн-Ля Рош Аг | Substituted 4-imidazoles, method for preparing and using them |
WO2008088937A1 (en) | 2007-01-12 | 2008-07-24 | Allergan, Inc. | Quinolynylmethylimidizoles as therapeutic agents |
WO2008086131A1 (en) | 2007-01-12 | 2008-07-17 | Allergan, Inc. | Naphthylmethylimidizoles as therapeutic agents |
US7868020B2 (en) | 2007-01-12 | 2011-01-11 | Allergan, Inc. | Quinolynylmethylimidizoles as therapeutic agents |
WO2008100456A2 (en) | 2007-02-13 | 2008-08-21 | Schering Corporation | Functionally selective alpha2c adrenoreceptor agonists |
ATE530547T1 (en) | 2007-02-13 | 2011-11-15 | Schering Corp | DERIVATIVES AND ANALOGUES OF CHROMENE AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS |
US8017642B2 (en) | 2007-02-13 | 2011-09-13 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
EP2155715B1 (en) * | 2007-05-14 | 2013-03-13 | Allergan, Inc. | ((phenyl)imidazolyl)methylheteroaryl compounds |
WO2009023752A1 (en) * | 2007-08-15 | 2009-02-19 | Allergan, Inc. | Adrenergic compounds |
US7902247B2 (en) | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
CA2712256A1 (en) * | 2008-01-18 | 2009-07-23 | Allergan, Inc. | Substitued-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors |
WO2009105504A2 (en) | 2008-02-21 | 2009-08-27 | Schering Corporation | Functionally selective alpha2c adrenoreceptor agonists |
US8324213B2 (en) | 2008-10-07 | 2012-12-04 | Merck Sharp & Dohme Corp. | Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators |
US20120225918A1 (en) * | 2011-03-03 | 2012-09-06 | Voom, Llc | Compositions and Methods for Non-Surgical Treatment of Ptosis |
BR112020009361A2 (en) | 2017-11-17 | 2020-10-13 | Cellix Bio Private Limited | compound of formula i, pharmaceutical composition to treat an eye disorder or complications thereof, method of synthesis of compound, method of treating an eye disorder or complications thereof in an individual who needs it and use of a compound |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU518569B2 (en) * | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
JPH01242571A (en) * | 1988-03-22 | 1989-09-27 | Mitsui Petrochem Ind Ltd | Production of imidazole derivative |
GB9520150D0 (en) * | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
US5750720A (en) * | 1996-03-28 | 1998-05-12 | Ortho Pharmaceutical Corporation | 4- (thien-3-yl)methyl!-imidazole analgesics |
US5621113A (en) * | 1996-03-28 | 1997-04-15 | Ortho Pharmaceutical Corporation | 4-[(thien-2-yl)methyl]-imidazole analgesics |
ZA988954B (en) * | 1997-10-02 | 1999-04-12 | Snow Brand Milk Products Co Ltd | Novel dihydronaphthalene compound and production process of the same |
AU744798B2 (en) * | 1997-12-04 | 2002-03-07 | Allergan, Inc. | Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors |
-
2000
- 2000-06-07 TW TW089111068A patent/TWI283669B/en not_active IP Right Cessation
- 2000-06-08 ES ES00939699T patent/ES2228544T3/en not_active Expired - Lifetime
- 2000-06-08 EP EP00939699A patent/EP1104407B1/en not_active Expired - Lifetime
- 2000-06-08 AU AU54749/00A patent/AU773668B2/en not_active Ceased
- 2000-06-08 CZ CZ2001864A patent/CZ2001864A3/en unknown
- 2000-06-08 RU RU2001107028/04A patent/RU2232154C2/en not_active IP Right Cessation
- 2000-06-08 HU HU0104390A patent/HUP0104390A3/en unknown
- 2000-06-08 AT AT00939699T patent/ATE283843T1/en not_active IP Right Cessation
- 2000-06-08 WO PCT/US2000/015795 patent/WO2001000586A1/en active IP Right Grant
- 2000-06-08 DE DE60016359T patent/DE60016359T2/en not_active Expired - Lifetime
-
2001
- 2001-09-07 HK HK01106343A patent/HK1035724A1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2001107028A (en) | COMPOUNDS AS SELECTIVE AGONISTS OF ALPHA-ADRENERGIC RECEPTORS 2B OR 2B / 2C | |
RU2000114169A (en) | SUBSTITUTED DERIVATIVES OF IMIDAZOL, possessing activity, similar activity of agonists, in relation to the adrenergic receptor ALPHA-2B or -2B / 2C | |
RU2324684C2 (en) | Pyrimidine derivatives | |
JP2977536B2 (en) | Phenyl- and aminophenyl-alkylsulfonamides and urea derivatives | |
JP2007505111A (en) | Non-sedating A-2 agonist 1- (2,3-dimethyl-phenyl) -ethyl-1,3-dihydro-imidazol-2-thione | |
EP0214058B1 (en) | Pharmaceutical composition containing histamine derivatives | |
CN101018546B (en) | (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators | |
RU98108027A (en) | IMIDAZOLE DERIVATIVES AFFECTING ALPHA2 RECEPTOR ACTIVITIES | |
RU2003127734A (en) | METALLOPROTEINASE INHIBITORS | |
RU2005113168A (en) | 2-pyridone derivatives as a neutrophilic elastase inhibitor | |
DE10233817A1 (en) | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | |
RU2007108861A (en) | TRIFTOMETHYL SUBSTITUTED BENZAMIDES AS KINASE INHIBITORS | |
RU2006136085A (en) | NEW COMPLEX ETHERS OF QUATERATED HINUCLIDINE | |
SK391292A3 (en) | 4-alkyimidazole derivatives | |
JP2003519228A5 (en) | ||
RU2005138366A (en) | DERIVATIVES OF BENZIMIDAZOLE, COMPOSITIONS CONTAINING THEM, THEIR PRODUCTION AND USE OF THEM | |
RU2012114718A (en) | Pyridine compounds of a condensed ring as subtype selective modulators of receptors of sphingosine-1-phosphate-2 (S1P2) | |
JP2013508384A (en) | Alpha adrenergic receptor modulator | |
DK2932968T3 (en) | CONNECTION TO TREATMENT OF ALFA-ADRENERG MEDIED CONDITIONS | |
KR840001019B1 (en) | Process for preparing substituted furan derivatives | |
AU2007207607A1 (en) | Treatment of inflammatory disorders with triazole compounds | |
RU2005115079A (en) | NEW COMPOUNDS OF N-HYDROXYTHIOMETRA, UREA, AMIDE COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS | |
EP1773740A4 (en) | Neurologically-active compounds | |
KR20040039436A (en) | Pharmaceutical composition | |
HU228775B1 (en) | Use of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence and pharmaceutical compositions containing them |